PaxMedica, Inc.: Nasdaq/NYSE listing notice — Nasdaq to delist PaxMedica common stock on May 2, 2024 due to minimum bid price noncompliance

PaxMedica, Inc.

Nasdaq Panel determined to delist PaxMedica common stock; trading suspended at open on May 2, 2024.
Reason: violation of Nasdaq minimum bid price requirement (Listing Rule 5550(a)(2)).
Company expects common stock to be eligible for quotation on OTC Pink Market under symbol PXMD.
Company has 15 days to request review by the Nasdaq Listing and Hearing Review Council.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PaxMedica, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 30, 2024, The Nasdaq Stock Market LLC (“Nasdaq”) notified PaxMedica, Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock and that trading of the Company’s securities will be suspended at the open of trading on May 2, 2024. The Company expects its common stock will be eligible for quotation on the OTC Pink Market under its existing symbol, “PXMD.” The Panel reached its decision because the Company is in violation of the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). The Company has 15 days after the date i

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-24-055841

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.